Catalent (CTLT) Tops Q2 EPS by 1c, Revenues Beat; Raises FY20 Revenue Guidance Above Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. META
4. NFLX
5. TSLA
6. ISRG
7. SMCI
8. GOOGL
9. RTX
10. USO

Go back to Catalent (CTLT) Tops Q2 EPS by 1c, Revenues Beat; Raises FY20 Revenue Guidance Above Consensus

Catalent, Inc. Reports Second Quarter Fiscal 2020 Results

February 3, 2020 7:30 AM EST

Q2'20 revenue of $721.4 million increased 16% as-reported, or 17% in constant currency, from Q2'19. Accelerated growth in the Biologics segment. Solid organic growth in the Softgel and Oral Technologies and Clinical Supply Services segments more than offset decline in the Oral and Specialty Delivery segment. Announcing further expansion of Biologics footprint with agreement to acquire MaSTherCell, a leading cell therapy development and manufacturing partner with facilities in Brussels, Belgium and Houston, Texas. Raising FY'20 financial guidance range, primarily due to continued growth of recently acquired... More